FDA label 52cf0df2-c3e1-41b6-afd0-db686da131d8
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- a3e521be-bdd7-406d-9791-749f75399c38
- SPL ID
- 52cf0df2-c3e1-41b6-afd0-db686da131d8
- Version
- 3
- Effective date
- 2013-06-04
- Source export date
- 2026-09-28
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/bb1af06e95bcf9567b07e56fcf3a03c0cac3c7c82ff89d4c970881174949e5b7/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:50:16
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | 52cf0df2-c3e1-41b6-afd0-db686da131d8 | id | |
| spl set id | a3e521be-bdd7-406d-9791-749f75399c38 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS: Chlordiazepoxide HCI and Clidinium Br Capsules may produce drowsiness and blurred vision. The patient should be warned about in engaging in hazardous work or activities requiring mental alertness, such as operating a motor vehicle or other machinery. Use caution when prescribing Chlordiazepoxide HCI and Clidinium Br Capsules concurrently with psychotropic agents, especially those that include MAD inhibitors and phenothiazines. Patients with impaired renal or hepatic function should be observed, along with patients being treated for anxiety or depression. Paradoxical reactions to chlordiazepoxide hydrochloride, e.g., excitement, stimulation and acute rage, have been reported in psychiatric patients and should be considered during Chlordiazepoxide HCI and Clidinium Br Capsules therapy.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS: When chlordiazepoxide hydrochloride has been used alone, drowsiness, ataxia and confusion have been reported in some patients, particularly the elderly and debilitated. These effects can be avoided in almost all instances by adjusting the dosage, and have occasionally been observed at the lower dosage ranges. In a few instances syncope has been reported. Also reported are isolated instances of skin eruptions, edema, nausea and constipation, extrapyramidal symptoms, minor menstrual irregularities, as well as increased and decreased libido. Such side effects have been infrequent and are generally controlled with reduction of dosage. Changes in EEG patterns have been observed in patients during and after chlordiazepoxide hydrochloride treatment. Blood dyscrasias, including agranulocytosis, jaundice and hepatic dysfunction have occasionally been reported during therapy with chlordiazepoxide hydrochloride. When chlordiazepoxide hydrochloride treatment is protracted, periodic blood counts and liver function tests are advisable. Typical of anticholinergic agents, adverse effects reported with use of Chlordiazepoxide HCI and Clidinium Br Capsules may include dry mouth, blurred vision, urinary hesitancy and constipation. Constipation occurred most often when combined with other spasmolytic agents and/or a restrictive, low residue diet. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.